Showing results (2711-2720 of 2,925) with videos related to

Sort By:
Pageof 293
The Journal of Pharmacology and Experimental Therapeutics|June 25, 2005
Inhibitory effects of 12-O-tetradecanoylphorbol-13-acetate alone or in combination with all-trans retinoic acid on the growth of cultured human pancreas cancer cells and pancreas tumor xenografts in immunodeficient miceGina E Avila, Xi Zheng, Xiao Xing Cui, et al.
Science Advances|July 8, 2016
Role of scaffold network in controlling strain and functionalities of nanocomposite filmsAiping Chen, Jia-Mian Hu, Ping Lu, et al.
Cancer Science|December 23, 2016
CS2164, a novel multi-target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti-tumor potencyYou Zhou, Song Shan, Zhi-Bin Li, et al.
European Journal of Pharmacology|April 21, 2009
Evidence that inhibition of insulin receptor signaling activity by PC-1/ENPP1 is dependent on its enzyme activityChen-Ni Chin, Qing Dallas-Yang, Franklin Liu, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|March 28, 2020
RNA-Sequencing, Connectivity Mapping, and Molecular Docking to Investigate Ligand-Protein Binding for Potential Drug Candidates for the Treatment of Wilms TumorJia-Yuan Luo, Shi-Bai Yan, Gang Chen, et al.
Cancer Research|March 21, 2020
Inactivation of the Prolyl Isomerase Pin1 Sensitizes BRCA1-Proficient Breast Cancer to PARP InhibitionMan-Li Luo, Fang Zheng, Wenying Chen, et al.
Lipids in Health and Disease|February 17, 2012
Cholesteryl ester transfer protein TaqIB polymorphism and its association with serum lipid levels and longevity in Chinese Bama Zhuang populationShang-Ling Pan, Fei Wang, Ze-Ping Lu, et al.
Scientific Reports|April 7, 2017
MicroRNA-140-5p inhibits hepatocellular carcinoma by directly targeting the unique isomerase Pin1 to block multiple cancer-driving pathwaysXingxue Yan, Zhendong Zhu, Shenmin Xu, et al.
Scientific Reports|October 5, 2016
Metabolomics reveals the mechanisms for the cardiotoxicity of Pinelliae Rhizoma and the toxicity-reducing effect of processingTao Su, Yong Tan, Man-Shan Tsui, et al.
Bioorganic & Medicinal Chemistry Letters|August 12, 2022
Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT)Timothy M Caldwell, Yu Mi Ahn, Stacie L Bulfer, et al.
Pageof 293